Psyence Biomedical files interim financials on Form 6-K

Psyence Biomedical Ltd. submitted a Form 6-K to provide investors with its unaudited condensed consolidated financial statements and management’s discussion and analysis for the three and six months ended September 30, 2025 and 2024.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Psyence Biomedical Ltd. submitted a Form 6-K to provide investors with its unaudited condensed consolidated financial statements and management’s discussion and analysis for the three and six months ended September 30, 2025 and 2024. These documents give updated insight into the company’s recent operating and financial performance between formal annual reports.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Psyence Biomedical Ltd. (PBM) file in this Form 6-K?

Psyence Biomedical filed a Form 6-K furnishing unaudited condensed consolidated financial statements and a related management’s discussion and analysis for the three and six months ended September 30, 2025 and 2024.

Which financial periods are covered in Psyence Biomedical’s latest Form 6-K?

The Form 6-K covers unaudited condensed consolidated financial statements and MD&A for the three-month and six-month periods ended September 30, 2025 and September 30, 2024.

Does the Psyence Biomedical (PBM) Form 6-K include management commentary?

Yes. Alongside the unaudited condensed consolidated financial statements, Psyence Biomedical included a Management’s Discussion and Analysis explaining and contextualizing results for the three and six months ended September 30, 2025 and 2024.

What exhibits are attached to Psyence Biomedical’s November 2025 Form 6-K?

The exhibits include unaudited condensed consolidated financial statements (Exhibit 99.1), the related Management’s Discussion and Analysis (Exhibit 99.2), and multiple Inline XBRL data files, including the instance, schema, calculation, definition, label, and presentation documents.

Who signed Psyence Biomedical Ltd.’s November 2025 Form 6-K?

The Form 6-K was signed on behalf of Psyence Biomedical Ltd. by Jody Aufrichtig, who is identified as the company’s Chief Executive Officer and Director as of the signature date in November 2025.

Why is Psyence Biomedical using Form 6-K for these interim results?

As a foreign private issuer, Psyence Biomedical uses Form 6-K to furnish interim financial statements and MD&A between annual reports, providing investors with updated information on its operations and financial position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/20/2025 - 04:01 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41937

Psyence Biomedical Ltd.

(Translation of registrant’s name into English)

121 Richmond Street West

Penthouse Suite 1300

Toronto, Ontario M5H 2K1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

Explanatory Note

Psyence Biomedical Ltd. (the “Company”) is filing this Form 6-K to file its unaudited interim consolidated financial statements for the three and six months ended September 30, 2025 and 2024 (the “Interim Financial Statements”), along with its corresponding Management’s Discussion and Analysis.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2025 and 2024.
99.2		Management Discussion and Analysis for the Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2025 and 2024.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 20, 2025

Psyence Biomedical Ltd.

By:	/s/ Jody Aufrichtig
Name:	Jody Aufrichtig
Title:	Chief Executive Officer and Director

Source: View Original Filing on SEC EDGAR